Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex
Authors:
- C. PecesCPC. Peces
- E. Cuesta-LopezECE. Cuesta-Lopez
- V. Perez-DuenasVPV. Perez-Duenas
- C. Vega-CabreraCVC. Vega-Cabrera
- S. AzorinSAS. Azorin
- R. SelgasRSR. Selgas
- 27 July 2010
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (11) , 3787-3791
Abstract
Tuberous sclerosis complex (TSC) is caused by constitutively activated mammalian target of rapamycin (mTOR) resulting in non-malignant tumours of several organs including renal angiomyolipomas (AMLs). AMLs may originate renal failure, hypertension and spontaneous life-threatening bleeding. Recent reports suggest a possible beneficial role of the mTOR inhibitor rapamycin for TSC. However, safety and efficiency of rapamycin in TSC patients as an anti-proliferative agent are still undefined. A 40-year-old man with sporadic TSC and a history of spontaneous bleeding from his left kidney AMLs received low-dose rapamycin for 12 months, and this was associated with a reduction in bilateral kidney AML volume, stabilization and even improvement of renal function. There was also a reduction of facial angiofibromas, improvement of blood pressure control and absence of AML bleeding over this time period. Brain lesion images remained stable, and no significant rapamycin-associated side effects were noted. To the best of our knowledge, this is the first report of a case of reduction in renal AML volume together with preservation of renal function in a patient with TSC receiving low-dose rapamycin. These data suggest that it could be the result of the anti-angiogenic, anti-fibrotic and anti-proliferative effects of rapamycin.Keywords
This publication has 12 references indexed in Scilit:
- Rapamycin as a Therapy of Choice After Renal Transplantation in a Patient With Tuberous Sclerosis ComplexTransplantation Proceedings, 2009
- Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin TreatmentThe Journal of Heart and Lung Transplantation, 2008
- Sirolimus Therapy in Tuberous Sclerosis or Sporadic LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Efficacy of Sirolimus in Treating Tuberous Sclerosis and LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complexEuropean Journal of Internal Medicine, 2007
- The Tuberous Sclerosis ComplexNew England Journal of Medicine, 2006
- Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis ComplexAmerican Journal of Kidney Diseases, 2006
- Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis ComplexPediatric Research, 2005
- Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse modelsGenes, Chromosomes and Cancer, 2004